Breast Cancer News

Higher Sensitivity With 1-View Digital Breast Tomosynthesis for Breast Cancer Detection

Higher Sensitivity With 1-View Digital Breast Tomosynthesis for Breast Cancer Detection

One-view digital breast tomosynthesis with a reduced compression force detected breast cancer with higher sensitivity and lower specificity than 2-view digital mammography.

Talazoparib Improves PROs in BRCA-Positive Triple-Negative Breast Cancer

Talazoparib Improves PROs in BRCA-Positive Triple-Negative Breast Cancer

Talazoparib resulted in better patient-reported outcomes compared with chemotherapy among women with TNBC and BRCA mutations in the EMBRACA trial.

20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer

20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer

A 20-year follow-up demonstrated a continued survival benefit with HDCT with HSCT for patients with early breast cancer and at least 9 involved axial lymph nodes.

Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer

Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer

Six months of treatment with trastuzumab is substantially more cost-effective than 12 months of therapy.

Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer

Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer

The drug combination was particularly beneficial for patients in the PD-L1-positive subgroup.

A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models

A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models

A tetravalent BiTE against HER2 and CD3 showed potent antitumor activity in models of HER2-positive cancer, supporting further clinical development.

Trastuzumab Biosimilar Demonstrated Equivalent Efficacy Across Clinical Settings

Trastuzumab Biosimilar Demonstrated Equivalent Efficacy Across Clinical Settings

Two biosimilars to trastuzumab were found to have efficacy equivalent to the sponsor product in both early-stage and metastatic breast cancer settings.

Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer

Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer

Treatment with chemotherapeutics promoted atrophy and mitochondrial damage in breast muscle cells.

Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response

Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response

Existing studies that summarize the risks of breast implants are not adequately powered to detect all harms, alleged authors of a study including nearly 100,000 patient outcomes.

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.

Breast Cancer Subtype May Be Predictive of Ipsilateral Breast Tumor Recurrence

Breast Cancer Subtype May Be Predictive of Ipsilateral Breast Tumor Recurrence

Radiotherapy after surgery may modify ipsilateral breast tumor recurrence risk among different subtypes of breast cancer.

Radiofrequency Ablation Plus Surgery May Improve Tumor Control in Early-Stage Breast Cancer

Radiofrequency Ablation Plus Surgery May Improve Tumor Control in Early-Stage Breast Cancer

Whether radiofrequency ablation is a superior treatment option to lumpectomy requires further investigation.

Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer

Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer

The role and impact of religiousness/spirituality in determining physical well-being among survivors of breast cancer is not well understood.

Copy Number Abnormalities May Inform Survival, Drug Resistance

Copy Number Abnormalities May Inform Survival, Drug Resistance

For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.

High-Risk Breast Cancer Patients May Not Be Adherent to Heart Failure Monitoring

High-Risk Breast Cancer Patients May Not Be Adherent to Heart Failure Monitoring

There is a paucity of data regarding the cardiotoxicity and the monitoring adherence habits of patients undergoing treatment with trastuzumab or anthracyclines, commonly used therapies among patients with HER2-positive breast cancer.

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.

Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific

Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific

Variations in the use and frequency of advanced imaging post-surgery in patients with breast cancer were observed across regions of the United States.

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Adding Ovarian Suppression May Improve Survival Outcomes in Premenopausal Breast Cancer

Adding Ovarian Suppression May Improve Survival Outcomes in Premenopausal Breast Cancer

Updated results of the SOFT and TEXT trial suggest that adding ovarian suppression to exemestane or tamoxifen could improve survival outcomes.

Trastuzumab Retreatment May Be Safe and Effective in Breast Cancer Recurrence

Trastuzumab Retreatment May Be Safe and Effective in Breast Cancer Recurrence

The effectiveness of trastuzumab in retreating patients with recurrence who received it during perioperative therapy is the focus of a new study.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs